HL

Notice of Allowability	Application No.	Applicant(s)	
	09/721,341	GOSLING ET AL.	
	Examiner	Art Unit	
	Bridget E. Bunner	1647	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. X This communication is responsive to the request for continued examination of 01 December 2004.			
2. X The allowed claim(s) is/are 25, 27, 37-41, and 43-52 (renumbered as claims 1-17, respectively).			
3. 🔀 The drawings filed on <u>26 November 2002</u> are accepted by the Examiner.			
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Da 8), 7. ☐ Examiner's Amend	ate	



Application/Control Number: 09/721,341

Art Unit: 1647

DETAILED ACTION

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

The claims of the instant application satisfy the enablement requirement under 35 U.S.C. § 112, first paragraph because, as asserted by Applicant, the specification provides guidance as to what amino acids could potentially be altered without affecting protein activity. Specifically, the specification discloses at page 33 and Figure 2A, the structural and functional homology of CCX CKR (SEQ ID NO: 2) to four other chemokines. Additionally, the claims of the instant application satisfy the written description requirement under 35 U.S.C. § 112, first paragraph because the CCX CKR fragments and variants bind specific chemokines (function) and have at least 90% sequence identity to SEQ ID NO: 2 (structure).

Furthermore, the petitions filed 01 December 2004 under 37 CFR 1.313(c)(2), 37 CFR 1.48(a) and 37 CFR 1.183 have been granted. Therefore, the inventorship of the instant application has been corrected and the current inventors listed are: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, and Thomas J. Schall.

Applicant has the right to file divisional or continuation applications to protect the inventions in the cancelled claims.

2. The art made of record and not relied upon is considered pertinent to applicant's disclosure:

Schall et al. U.S. Patent 6,699,677

Gosling et al. U.S. Patent 6,835,547

Art Unit: 1647

The above-cited patents were considered by the Examiner because these patents were recently issued and have common inventors and subject matter with the instant application.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bridget E. Bunner whose telephone number is (571) 272-0881. The examiner can normally be reached on 8:30-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BEB Art Unit 1647 February 23, 2005